Salesforce customers can now benefit from Real World Data collection and patient engagement for all clinical studies

SAN DIEGO, April 12, 2022 -- Seqster PDM, Inc. ("Seqster") the leading patient-centric healthcare technology company, today announced it has launched SeqsterOS, the Operating System for Patient Registries and clinical studies on Salesforce AppExchange, empowering life science enterprises to seamlessly integrate patient-consented Real World Data, including electronic health records (EHR), genomics, and device data, with a patient engagement layer for their clinical studies.

Integrated directly with Salesforce Health Cloud, SeqsterOS is currently available on AppExchange.

"SeqsterOS app is a welcome addition to AppExchange, as they power digital transformation for clients by empowering both clinical trials and patients on Salesforce Health Cloud," said Woodson Martin, EVP & GM of Salesforce AppExchange. "AppExchange is constantly evolving to connect customers with the right apps and experts for their business needs."

SeqsterOS automates real-time Real World Data (“RWD”) collection while improving the participant journey. Life science enterprises benefit from improved study participant engagement and retention. Study participants and researchers benefit from longitudinal health information essential for long-term observational studies and effectively conducting health economics & outcomes research (HEOR). 

SeqsterOS on Health Cloud offers these additional benefits:

• FDA 21 CFR Part 11 Compliance for drug submissions
• De-identification and tokenization of data 
• E-Consent, eCOA
• ePRO

“SeqsterOS empowers researchers with high-quality, high-fidelity health data directly from any source that can be readily utilized for analytics, AI, and RWE, accelerating the drug discovery cycle, all while improving the patient journey. By joining Salesforce AppExchange, we introduce our solution at scale for life science enterprise clients for application in clinical studies, whether in the traditional site-based setting or in decentralized trials,” said Ardy Arianpour, CEO & Co-Founder of Seqster.